Update on sumatriptan: New progress in migraine treatment

Therapy

Volumn 2, Issue 3, 2005, Pages 349-356

  Dahlöf, Carl ^a  

^a Gothenburg Migraine Clinic   (Sweden)

Author keywords

Formulations; Management; Migraine; Sumatriptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

AREA UNDER THE CURVE; BURNING SENSATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; MIGRAINE; NAUSEA; NEUROTRANSMISSION; REVIEW; SENSORY DYSFUNCTION; TASTE DISORDER;

EID: 20344369995     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.3.349     Document Type: Review

References (39)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the USA: data from the American Migraine Study II. Headache 41, 646-657 (2001).
2. Mannix LK. Epidemiology and impact of primary headache disorders. Med. Clin. North. Am. 85, 887-895 (2001).
3. Anthony M, Rasmussen BK. Migraine without aura. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Raven Press, NY, USA 255-261 (1993).
4. Dahlöf C. Sumatriptan: pharmacological basis and clinical results. Curr. Med. Res. Opin. 17(Suppl. 1), S35-S45 (2001).
5. Gladstone JP, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs 63, 2285-2305 (2003).
6. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst. Rev. CD002915 (2003).
7. Rapoport A. The sumatripran nasal spray: a review of clinical trials. Cephalalgia 21(Suppl. 1), 13-15 (2001).
8. Dahlöf C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 19, 769-778 (1999).
9. Dahlöf C. Clinical efficacy and tolerability of sumatriptan tablets and suppository in the acute treatment of migraine: a review of data from clinical trials. Cephalalgia 21(Suppl. 1), 9-12 (2001).
10. McAlhany A. Efficacy of sumatriptan in the treatment of migraine: a review of the literature. J. Neurosci. Nurs. 33, 270-277, 285 (2001).
11. Dechant KL, Clissold SP. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster Headache Drugs 43, 776-798 (1992).
12. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine - new insights. Can. J. Neurol. Sci. 26(3), S12-S19 (1999).
13. Humphrey PP, Feniuk W, Perren MJ et al. The pharmacology of the novel 5-HT-1-like receptor agonist, GR43175. Cephalalgia 9, 23-33 (1989).
14. Humphrey PP, Feniuk W, Marriott AS et al. Preclinical studies on the antimigraine drug, sumatriptan. Eur. Neurol. 31, 282-290 (1991).
15. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster Headache Drugs 47, 622-651 (1994).
16. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 55, 889-922 (1998).
17. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 18, 532-538 (1998).
18. Dahlöf C. Integrating the triptans into clinical practice. Curr. Opin. Neurol. 15, 318-322 (2002).
19. Dodick DW, Silberstein S, Dahlöf C. Is there a preferred triptan? Headache 42, 1-7 (2002).
20. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin. Investig. Drugs 10, 1831-1845 (2001).
21. Millson DS. Rational migraine management: optimizing treatment with the triptans. Funct. Neurol. 15(Suppl. 3), 182-191 (2000).
22. Walls C, Lewis A, Bullman J et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr. Med. Res. Opin. 20, 803-809 (2004).
23. Carpay J, Schoenen J, Ahmad F et al. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther. 26, 214-223 (2004).
24. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N. Engl. J. Med. 325, 316-321 (1991).
25. Cady RK, Wendt JK, Kirchner JF, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. J. Am. Med. Assoc. 265, 2831-2835 (1991).
26. Dahlöf C. Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials. Presentated at: Imigran - 10 years of improving the lives of migraine patients Rome, Italy (2000).
27. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch. Fam. Med. 7, 234-240 (1998).
28. Pfaffenrath V, Cunin G, Sjonell G et al. Efficacy and safety of sumatriptan tablets in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 38, 184-190 (1998).
29. Sargent J, Kirchner JR, Davis R et al. Oral sumatriptan is effective and well-tolerated for the acute treatment of migraine: Results of a multicenter study. Neurology 45 (Suppl. 7), S10-S14 (1995).
30. Cutler N, Mushet GR, Davis R et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 45(Suppl. 7), S5-S9 (1995).
31. Cady RK, Sheftell F, Lipton RB et al. Effects of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin. Ther. 22, 1035-1048 (2000).
32. Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin. Proc. 78, 1214-1222 (2003).
33. Pfaffenrath V, Salonen R. Clinical efficacy and tolerability of sumatriptan suppository in the acute treatment of migraine: A review of data from clinical trials. Eur. J. Neurol. 5 (Suppl. 3), S49 (1998).
34. Savani N, Loftus J, Boswell, D. A randomized double-blind, placebo-controlled, parallel group evaluation of sumatriptan 50-mg and 100-mg tablets administered during the mild pain phase of a menstrually associated migraine attack. Cephalalgia 22, 606 (2002).
35. Nett R, Landy S, Shackelford S et al. Pain-free efficacy after treatment with sumatriptan in the mild-pain phase of menstrually associated migraine. Obstet. Gynecol. 102, 835-842 (2003).
36. Dodick D, Lipton RB, Martin V et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44, 414-425 (2004).
37. Valentgas P, Cole A, Mo J et al. Triptan use is not associated with increased risk of severe vascular events in migraine patients. Eur. J. Neurol. 9(Suppl. 2), 45 (2002).
38. Hall GC, Brown MM, Mo J et al. Migraine, triptan treatment and the risk of cardiovascular disease, stroke and mortality. Eur. J. Neurol. 9(Suppl. 2), 150 (2002).
39. Matchar DB, Young WB, Rosenberg JH et al. Multispecialty consensus on diagnosis and treatment of headache: pharmacological management of acute attacks. Neurology 54 (2000).